Articles / Ice psychosis: what is it, and why do only some users get it?
writer
Addiction Psychiatrist, Lecturer, Monash University
0 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
These are activities that require reflection on feedback about your work.
These are activities that use your work data to ensure quality results.
There is growing concern about crystal methamphetamine (ice) use in Australia and internationally, in part because of the psychological effects of the drug. Although most people who use ice do not experience psychological problems, about one in three people who use it regularly report experiencing psychosis in their lifetime.
Research also suggests that up to 30% of people who experience ice psychosis go on to develop a long-term psychotic illness such as schizophrenia or bipolar disorder. Our new study aimed to find out why some ice users are more likely to experience psychosis than others.
Read more: Ice causes death in many ways, overdose is just one of them
RSV Prevention in Infants and Pregnant Women
STIs – Common and Tricky Cases
Role of Testosterone During Menopause - Evidence vs Hype
Vision and Driving Fitness: Key Insights for Health Practitioners
writer
Addiction Psychiatrist, Lecturer, Monash University
Yes
No
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease